Venous thrombosis (VT) is one of the most frequent vascular diseases which most often affects deep (deep vein thrombosis) and superficial veins of lower limbs. Venous thrombosis is a multifactorial disease related to different risk factors. These risk factors predispose apparently healthy patients to venous thromboembolic disease and are likely to trigger thrombotic episodes in patients with prothrombotic tendencies. Acquired or inherited risk factors responsible for thromboembolic events are identifiable in most patients. 1 However, the basic pathogenic mechanisms in venous thromboembolism (VTE) with known or unknown risk factors remain unexplained. The most probable pathophysiological mechanism which cause VTE involve the Virchow triad: endothelial damage, blood stasis, and hypercoagulability. 2, 3 All these pathogenic mechanisms are usually interrelated and most probably the thrombotic process starts with damage of the venous wall. This damage can be caused by mechanical forces (turbulent blood flow or immobilization) or biochemical factors (abnormal constituents of blood, like inflammation mediators, homocysteine, procoagulant factors). 4 Most probably, a functional deterioration of the vessel wall-endothelial dysfunction (ED) is important. 5 Functional capability of the vessel wall, particularly of the endothelium, is an important protective mechanism that ensures circulatory homeostasis and prevents thrombus formation. The main function of the endothelium is to regulate systemic blood flow and tissue perfusion. In addition, the endothelium acts as a barrier that selectively controls the movement of fluids and molecules between circulating blood and surrounding tissue. 6 The endothelium also regulates the recruitment and extravasation of proinflammatory leukocytes in response to tissue damage and infection through the expression of cell adhesion molecules and cytokines. 7 The endothelium is also involved in the recanalization of obstructive fibrin clots. The endothelium expresses different molecules that regulate the activation of platelets and coagulation cascade, maintaining blood flow and preventing thrombus formation after vessel injury. 8 Endothelial dysfunction, which is characterized by an imbalance between relaxing and contracting factors, procoagulant and anticoagulant substances, and between proinflammatory and anti-inflammatory mediators, plays a significant role in the pathogenesis of atherosclerosis and probably also in the development of venous thromboembolic disease. 9 The common mechanism through which different risk factors cause ED is most probably increased oxidative stress and consequent decreased bioavailability of nitric oxide (NO).
Endothelial Dysfunction and VT
Healthy endothelial cells, unlike extravascular cells, have anticoagulant and antithrombotic properties. This is due to secretion of antiplatelet agents, including prostacyclin and NO. Local generation of thrombin causes a series of receptor-mediated endothelial cell functional responses, while the surface of the endothelium is additionally the site for inactivation of thrombin by antithrombin and its conversion to a coagulation inhibitor by interaction with thrombomodulin. 10, 11 Endothelial cells are also sources of circulating and tissue-type plasminogen activator. 12 Reduced venous wall shear stress induces hypoxia and stimulates release of P-selectin and von Willebrand factor (vWF) from endothelial cells thus promoting thrombus formation. 13 Once the endothelial cells become activated they play an essential role in the generation of thrombin through the expression of procoagulant factors that contribute to both the initiation and propagation of thrombus generation.
In the blood coagulation cascade, thrombin generation is initiated by activation of the extrinsic pathway triggered by activation of the factor VIIa or by activation of the intrinsic pathway. Activated endothelial cells as well as adhered leukocytes express tissue factor on the cell surface in response to vascular injury or inflammatory stimuli. Therefore, activated endothelial cells have an important role in the pathogenesis of thrombosis. 14 
Determination of ED and Its Involvement in VTE
Different invasive and noninvasive techniques have been used to explore the pathobiology of the endothelium. The peripheral arteries, because of their accessibility, represent the basis for assessment of endothelial function and ED. Flow-mediated dilation (FMD) of the peripheral conduit arteries is a frequently used test of endothelial function. The FMD measures the endothelial vasomotor response during reactive hyperemia, but it does not provide information concerning vasoreactivity at rest. A new technique-low-flow-mediated constriction (L-FMC)-provides complementary information to that of FMD, measuring the decrease in the forearm conduit arteries diameter that occurs in response to the decrease in blood flow during occlusion. 15 The L-FMC is mostly not based on NO availability but is mediated by other substances: prostacyclin and endothelin 1. 16, 17 Peripheral arterial tonometry evaluates pulse wave amplitude which is an indicator of endothelial function of small vessels and microcirculation. 18 The determination of venous endothelial function is more complicated and invasive and is less reproducible than FMD. 19 Microinvasive techniques such as the dorsal hand vein dilation capability and radionuclide assessment of changes in the volume of legs provide limited information about venous endothelial function. [20] [21] [22] [23] However, as ED is expected to be a systemic disorder affecting the whole circulatory system (arteries, veins, and microcirculation), determination of endothelial function of peripheral arteries may also provide insight into venous functional status.
19,24
Deep Vein Thrombosis Is Accompanied by ED Studies confirmed the relationship between ED and VT. Italian investigators were the first to show that in patients with idiopathic VT, endothelial function deteriorates compared with healthy patients. 25 This study showed that ED was a particular characteristic of patients with unprovoked VTE and that impairment of endothelial function in patients with spontaneous VTE was significantly associated with higher levels of markers of endothelial activation in the plasma (eg, vWF and soluble P-selectin). We showed that idiopathic VT is associated with impaired flow-mediated and glycerin trinitrate-mediated vasodilatory response of the brachial artery. 26 This suggests a relationship between VTE and atherosclerosis. We also showed that idiopathic VT is associated with long-term increased levels of markers of endothelial damage (vWF and P-selectin). 27 Endothelial dysfunction, which promotes coagulation, represents a cross talk between the arterial and venous systems and there are similar, or even identical, risk factors for both arterial atherosclerotic and venous thromboembolic diseases (age, obesity, hyperlipidemia, inflammation, and smoking), causing endothelial damage and increasing the thrombotic potential in the arterial and venous systems. Diabetes mellitus which is an established risk factor for atherosclerotic cardiovascular disease was shown to be related to prothrombotic state due to deterioration of primary hemostasis caused by ED and platelet activation. Diabetes mellitus enhances oxidative stress and decreases expression of protective endothelial factors, particularly NO. Therefore, diabetes promotes procoagulant state and VTE through deterioration of endothelial function. 28, 29 Hypertension which is one of the most important risk factors for atherothrombotic disease is probably also related to increased risk of VTE. Results from the MAinISar-THROmbosis registry suggested that arterial hypertension was an independent risk factor for recurrent VTE. 30 As in both diseases endothelial function deteriorates, 26, 31 ED could be the link between these 2 diseases. This is in agreement with the reports of efficacy of some antihypertensive drugs on risk of VTE. The study of Belattar and coworkers showed that angiotensin II receptor blockers are significantly associated with reduced risk of VTE, 32 and these drugs are known to improve endothelial function that could prevent VTE. 33 Further studies showed that physical exercise that improves endothelial function may prevent recurrent VTE. 34, 35 Involvement of ED in venous thrombogenesis is also supported by effect of heparin on venodilation. It was shown that heparin besides its anticoagulant activity also provokes endothelium-dependent venodilation which is a consequence of increased bioavailability of NO and improvement in venous endothelial function. 36 The metabolic syndrome represents a significant risk of both diseases; the activation of the coagulation system in the arterial as well as in venous tree is related to increased levels of proinflammatory and proatherogenic mediators (leptin, tumor necrosis factor a, interleukin 6) in patients with the metabolic syndrome. 37 Also other nonclassical risk factors like hyperhomocysteinemia, factor V Leiden, and lupus anticoagulants, which cause endothelial damage, represent a potential risk of both atherosclerosis and VT. 38 Therefore, an interrelationship between atherosclerosis and VTE does exist and ED most probably represents the link between the 2 diseases. In this context, a relationship was found between manifest atherosclerotic disease and VTE. Recent data indicate that there is a link between VTE in patients with asymptomatic or clinical manifestations of atherothrombosis as well as the risk of incident atherosclerotic events in patients with previous manifestations of VTE. 39 In another study, women with a history of myocardial infarction had 2.1-fold higher risk of VTE. 40 There are also data indicating a link between VT and preclinical atherosclerosis. 41 In patients with idiopathic VT, intima-media of carotid and femoral arteries was significantly thicker and the prevalence of the atherosclerotic plaques was higher in patients than in healthy patients. 41 The association between VTE and atherosclerotic disease is also supported by similar effective preventive measures, including lifestyle measures, and the use of drugs in both diseases. There is evidence that statins and smoking cessation reduce the risk of VTE. 42, 43 Endothelial Dysfunction-A Cause or Consequence of VT?
This is a relevant question because if ED is present before VT, it will represent a risk factor that is most probably a common denominator of harmful known and unknown factors that increase thrombogenicity. Endothelial dysfunction represents the earliest measurable functional deterioration of the vessel wall which is systemic and may affect both the arterial and venous systems.
Several studies showed that patients who survived acute VTE have long-term deteriorated (up to 4 years) endothelial function. The same was also shown for patients with complete recanalization of deep veins after an acute VTE. This suggests that the impairment of endothelial function is most probably a primary pathophysiological state that precedes the development of VT and not its consequence. 25, 27, 41 
Conclusions
Endothelial dysfunction is an established pathogenic mechanism of atherosclerosis, and recent data indicate that it has an important role in the pathogenesis of VT. The endothelium affects hemostasis as it is the source of many important hemostatic regulatory molecules. Therefore, deterioration of endothelial cell function may be involved in the pathogenesis of thrombosis. Basic and clinical studies confirmed the relationship between ED and VT, particularly in patients with unprovoked VTE. Endothelial dysfunction also represents the cross talk between the arterial and venous system and is most probably a common denominator of the harmful effects of similar risk factors for atherosclerosis and VT. Determination of venous ED in vivo is much more complicated than in the arterial system. However, as ED is a systemic disorder, with measurement of endothelial function in peripheral arteries, it is possible to extrapolate the status of endothelial function to veins. In the future, ED could be recognized as a risk factor for VT. Presumably, correcting the same variables that adversely affect the arterial endothelium will also help decrease VT risk.
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